Ticker: CADL

Snapshot - Candel Therapeutics, Inc. (NASDAQ: CADL) What's happening inside the company (quick summary) - Cash-rich for now: management reports cash & cash equivalents of about $100.7 million at June 30, 2025 and expects funding into Q1 2027. - Clinical progress driving expense but also value: po...

Candel Therapeutics, Inc. (NASDAQ: CADL) is a clinical-stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies for cancer treatment. As of March 31, 2025, the company reported progress in its clinical trials, ongoing strategic partnerships, and faced various fina...

Shares of Candel Therapeutics (NASDAQ: CADL) soared 150% after positive phase 3 trial results for CAN-2409, an innovative viral immunotherapy for localized prostate cancer. The treatment shows significant improvement in disease-free survival, with further FDA discussions anticipated.